| Kimberly Landwehr, OD | |
|
21 Park Pl, Appleton, WI 54914-8872 | |
| (920) 739-4361 | |
| (920) 739-6368 |
| Full Name | Kimberly Landwehr |
|---|---|
| Gender | Female |
| Speciality | Optometry |
| Experience | 26 Years |
| Location | 21 Park Pl, Appleton, Wisconsin |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1033129515 | NPI | - | NPPES |
| 38622500 | Medicaid | WI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | WI2734 (Wisconsin) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Valley Eye Associates | 5395633580 | 24 |
News Archive
Treating prostate cancer with higher doses of proton therapy over a shorter amount of time leads to similar outcomes when compared to standard dose levels and treatments and is safe for patients, according to a new study examining the risk of long-term side-effects from the treatment.
Health Discovery Corporation, the molecular diagnostics company that launched MelApp, the first SVM-based image analysis iPhone app for melanoma risk assessment is featured in this month's Men's Health Magazine.
Sanofi-aventis and Regeneron Pharmaceuticals, Inc. announced that the Phase III VELOUR trial evaluating the investigational agent ZALTRAP, also known as VEGF Trap, in combination with the FOLFIRI chemotherapy regimen versus a regimen of FOLFIRI plus placebo met its primary endpoint of improving overall survival in the second-line treatment of metastatic colorectal cancer.
Breast cancer patients, their families and advocates expressed extreme disappointment at today's Food and Drug Administration (FDA) decision to remove the anti-cancer drug Avastin from the approved medication list for treatment of late stage breast cancer.
› Verified 7 days ago
| Provider Name | Valley Eye Associates |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1699789032 PECOS PAC ID: 5395633580 Enrollment ID: O20040309000706 |
News Archive
Treating prostate cancer with higher doses of proton therapy over a shorter amount of time leads to similar outcomes when compared to standard dose levels and treatments and is safe for patients, according to a new study examining the risk of long-term side-effects from the treatment.
Health Discovery Corporation, the molecular diagnostics company that launched MelApp, the first SVM-based image analysis iPhone app for melanoma risk assessment is featured in this month's Men's Health Magazine.
Sanofi-aventis and Regeneron Pharmaceuticals, Inc. announced that the Phase III VELOUR trial evaluating the investigational agent ZALTRAP, also known as VEGF Trap, in combination with the FOLFIRI chemotherapy regimen versus a regimen of FOLFIRI plus placebo met its primary endpoint of improving overall survival in the second-line treatment of metastatic colorectal cancer.
Breast cancer patients, their families and advocates expressed extreme disappointment at today's Food and Drug Administration (FDA) decision to remove the anti-cancer drug Avastin from the approved medication list for treatment of late stage breast cancer.
› Verified 7 days ago
| Provider Name | Fox Valley Family Eye Care Sc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1245661875 PECOS PAC ID: 1456589670 Enrollment ID: O20140116000180 |
News Archive
Treating prostate cancer with higher doses of proton therapy over a shorter amount of time leads to similar outcomes when compared to standard dose levels and treatments and is safe for patients, according to a new study examining the risk of long-term side-effects from the treatment.
Health Discovery Corporation, the molecular diagnostics company that launched MelApp, the first SVM-based image analysis iPhone app for melanoma risk assessment is featured in this month's Men's Health Magazine.
Sanofi-aventis and Regeneron Pharmaceuticals, Inc. announced that the Phase III VELOUR trial evaluating the investigational agent ZALTRAP, also known as VEGF Trap, in combination with the FOLFIRI chemotherapy regimen versus a regimen of FOLFIRI plus placebo met its primary endpoint of improving overall survival in the second-line treatment of metastatic colorectal cancer.
Breast cancer patients, their families and advocates expressed extreme disappointment at today's Food and Drug Administration (FDA) decision to remove the anti-cancer drug Avastin from the approved medication list for treatment of late stage breast cancer.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Kimberly Landwehr, OD 21 Park Pl, Appleton, WI 54914-8872 Ph: (920) 739-4361 | Kimberly Landwehr, OD 21 Park Pl, Appleton, WI 54914-8872 Ph: (920) 739-4361 |
News Archive
Treating prostate cancer with higher doses of proton therapy over a shorter amount of time leads to similar outcomes when compared to standard dose levels and treatments and is safe for patients, according to a new study examining the risk of long-term side-effects from the treatment.
Health Discovery Corporation, the molecular diagnostics company that launched MelApp, the first SVM-based image analysis iPhone app for melanoma risk assessment is featured in this month's Men's Health Magazine.
Sanofi-aventis and Regeneron Pharmaceuticals, Inc. announced that the Phase III VELOUR trial evaluating the investigational agent ZALTRAP, also known as VEGF Trap, in combination with the FOLFIRI chemotherapy regimen versus a regimen of FOLFIRI plus placebo met its primary endpoint of improving overall survival in the second-line treatment of metastatic colorectal cancer.
Breast cancer patients, their families and advocates expressed extreme disappointment at today's Food and Drug Administration (FDA) decision to remove the anti-cancer drug Avastin from the approved medication list for treatment of late stage breast cancer.
› Verified 7 days ago
Paul K Thompson, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 1301 E Northland Ave, Suite A, Appleton, WI 54911 Phone: 920-734-8714 Fax: 920-734-8785 | |
Optivision Eye Care Llp Optometrist Medicare: Medicare Enrolled Practice Location: 223 S Nicolet Rd, Appleton, WI 54914 Phone: 920-733-5888 Fax: 920-733-5151 | |
Dr. Katie Abata, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 21 Park Pl, Appleton, WI 54914 Phone: 920-739-4361 Fax: 920-739-6368 | |
Maya Jillian Pollock, OD Optometrist Medicare: Medicare Enrolled Practice Location: 1225 W Northland Ave, Appleton, WI 54914 Phone: 920-731-2020 Fax: 920-733-2117 | |
Mark Wade, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 2700 W College Ave, Appleton, WI 54914 Phone: 920-735-9580 | |
Sullivan Eye Center, S.c. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 1195 N Casaloma Dr, Appleton, WI 54913 Phone: 920-734-0400 Fax: 920-734-9054 |